Roche Holding (OTC:RHHBY) announced last week that new clinical data showed that Avastin improved the chances of removal of mestastatic lesions in people with colorectal cancer.
Data showed that a large number of patients treated with Avastin combined with regular chemotherapy had their lesions completely removed. The trial was conducted with 1,965 patients with inoperable colorectal cancer. Of those in the trial 12% became eligible and underwent surgery and of the 12% 79% saw complete removal of the lesions.
"This outcome with Avastin is higher than has been previously seen in trials with other biologics/chemotherapy combinations," Roche said in a statement.
Avastin is the first in a class of drugs that tries to starve tumors of their blood and nutrients.
» Roche from PharmaGazette
Roche of Switzerland lands at #5 ($4.09 Eur) in the top 15 R&D spenders and #6 in overall sales. The company spent 2007 restructuring its research facilities and divided R&D into 5 categories: oncology, virology, inflammation, metabolism a... [Read More]
Tracked on: December 11, 2007 1:12 PM | Permalink to Trackback